Add time:09/03/2019         Source:sciencedirect.com

BackgroundSomatostatin analogs are the backbone of neuroendocrine neoplasms treatment. Biliary stone disease is a potentially severe adverse event of somatostatin analogs: an increased incidence has been reported in somatostatin analogs-treated acromegalic patients, but studies on patients with neuroendocrine neoplasms are lacking.

We also recommend Trading Suppliers and Manufacturers of somatostatin 34 (cas 132894-19-0). Pls Click Website Link as below: cas 132894-19-0 suppliers